Exanthema Market Report 2025

The exanthema market size has grown steadily in recent years. It will grow from $2.18 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth during the historical period can be attributed to factors such as higher healthcare spending, increased awareness about vaccination, rising disposable incomes, greater understanding of skin disorders, and a stronger focus on early detection.

The exanthema market size is expected to see steady growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period can be attributed to increased investments in research and development, a higher prevalence of viral and bacterial infections, a growing emphasis on telemedicine, expanding government initiatives, and a rising demand for oral medications. Key trends during this period include advancements in treatment approaches, innovations in diagnostic techniques, technological progress, breakthroughs in medical research and technology, and the development of assistive technologies.

The increasing prevalence of viral infections is expected to drive the growth of the exanthema market in the coming years. Viral infections are illnesses caused by viruses that invade and replicate within the body’s cells, resulting in various symptoms and diseases. Factors such as global travel, urbanization, climate change, and weakened immunity in populations are contributing to the rising frequency of viral infections. As more cases present with skin rashes, there is a growing need for effective exanthema treatments. Exanthema, which serves as a visible immune response to viral infections, plays a role in expelling pathogens, signaling immune activation, and assisting in diagnosis by showing the body’s fight against the virus. For example, according to the Centers for Disease Control and Prevention (CDC), between 2022 and 2024, the percentage of individuals with IgM antibodies, which indicate a recent Parvovirus B19 infection, remained below 3%, but surged to 10% by June 2024. The most significant rise occurred among children aged 5-9, where the prevalence increased from 15% to 40% during this period. As a result, the increasing prevalence of viral infections is driving the growth of the exanthema market.

Companies operating in the exanthema market are making strides in developing new therapeutics, including intramuscular (IM) administration of vaccines and antiviral treatments. This method, which involves delivering vaccines or medications directly into the muscle tissue via a syringe and needle, ensures quick absorption into the bloodstream. By leveraging the rich blood supply in the muscles, the IM administration prompts a therapeutic or immune response, improving the efficacy of the treatment. For example, in March 2023, Merck & Co. Inc. announced that the FDA had approved the IM administration route for its MMRV vaccines - M-M-R II, VARIVAX, and ProQuad. This method offers greater stability and efficacy for these live-virus vaccines compared to other administration methods, making it a key step in enhancing public health efforts to prevent severe viral infections.

In September 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for $1.2 billion. Dermavant Sciences is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics in immunodermatology. This acquisition strengthens Organon’s position in the dermatology field and aligns with its objectives to expand its portfolio with cutting-edge therapies.

Major players in the exanthema market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Abbott Laboratories, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Amgen Inc., Daiichi Sankyo Company Limited, Biological E. Limited, Zydus Lifesciences Limited, Bio Farma, Meridian Bioscience Inc., West-Ward Pharmaceutical Corp., Trinity Biotech plc, Biosynth Srl, Creative Diagnostics, Taj Pharmaceuticals Limited, TestLine Clinical Diagnostics s.r.o., The Native Antigen Co. Ltd., and QED Bioscience Inc.

North America was the largest region in the exanthema market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in exanthema report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the exanthema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Exanthema is a term used to describe a widespread skin rash or eruption, often resulting from a viral infection such as measles, rubella, or chickenpox (varicella). It plays a crucial role in diagnosing and identifying viral illnesses, as the rash's specific characteristics can help healthcare professionals determine the cause of the infection and decide on the most suitable treatment and management approaches.

The primary types of exanthema include bacterial, viral, and other forms. Bacterial exanthema is caused by infections from bacteria such as Streptococcus or Staphylococcus, leading to skin rashes. Treatment options involve topical medications, systemic therapies, and supportive care, with diagnostic methods including clinical examination, laboratory tests, and imaging techniques. Common conditions associated with exanthema include rubeola, rubella, erythema infectiosum, and roseola infantum. These diagnostic and treatment approaches are used by various healthcare providers, including hospitals, homecare services, and specialty centers.

The exanthema market research report is one of a series of new reports that provides exanthema market statistics, including the exanthema industry global market size, regional shares, competitors with the exanthema market share, detailed exanthema market segments, market trends, and opportunities, and any further data you may need to thrive in the exanthema industry. This exanthema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The exanthema market consists of revenues earned by entities by providing services such as antiviral treatment services, vaccination services, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The exanthema market also includes sales of topical corticosteroids, antihistamines, immunosuppressants, antiviral medications, and moisturizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.